The global concern surrounding cardiovascular health continues to grow, prompting many of us to explore the supportive benefits offered by dietary supplementation. In recent years, researchers have placed a significant emphasis on understanding the role of arterial stiffness in cardiovascular health. Additionally, they have made groundbreaking discoveries regarding the vitamin K-dependent protein Matrix Gla Protein (MGP). Through its many clinical trials, MenaQ7® is the vitamin K2 brand shown to effectively activate this critical cardio-supporting protein.
Vitamin K2 and Matrix Gla Protein (MGP)
Matrix Gla Protein (MGP) stands out as the most powerful prohibitor of vascular calcification, provided that the body has sufficient Vitamin K2 to activate it. Unfortunately, with vitamin K2 being almost completely void from typical Western diets, it is no wonder most people have deficient or insufficient levels of vitamin K2.
The Clinically Proven Vitamin K2 as MK-7 for Heart Health
Enter MenaQ7®: the clinically proven Vitamin K2 as MK-7. Our pioneering studies – randomized, double-blind, placebo-controlled trials – have demonstrated the remarkable benefits of MenaQ7®. One groundbreaking study, over the course of three years, showed that daily consumption of a nutritional dose of 180 mcg of MenaQ7® inhibited age-related arterial stiffening and improved arterial elasticity — a key aspect of maintaining a healthy cardiovascular system.
By choosing MenaQ7® for your supplement brand, be assured your ingredient is backed by scientific evidence confirming it supports robust heart health.
Learn more about the power of MenaQ7® and how the essence of this ingredient meets the top selection criteria of supplement buyers: Proof that it works!